A Study of XMT-1660 in Participants With Solid Tumors

Active:	Yes
Cancer Type:	Solid Tumor Unknown Primary	NCT ID:	NCT05377996
Trial Phases:	Phase I	Protocol IDs:	MER-XMT-1660-1 (primary) NCI-2022-04696
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Mersana Therapeutics
NCI Full Details:	http://clinicaltrials.gov/show/NCT05377996

Summary

A Study of XMT-1660 in Solid Tumors

Objectives

This first-in-human (FIH) study will test the safety and side effects of a drug called
XMT-1660. A side effect is anything a drug does to the body besides treating the disease.

Participants in the study will have cancer that has come back after a period of time
during which the cancer could not be detected (recurrent), spread in the body near where
it started (advanced) or spread through the body (metastatic).

The study will have two parts. The first part called Dose Escalation will find out how
much XMT-1660 should be given to participants. The second part called Dose Expansion will
use the dose found in the first part to find out how safe XMT-1660 is and if it works to
treat solid tumor cancers.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.